CDC-RFA-EH-24-0044: Centers of Excellence to Enhance Disease Detection in Newborns
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Centers for Disease Control - NCEH notices from 2024.
Centers for Disease Control - NCEH offered grants of up to $1.0 million (at least $750,000) to any type of organization. It expected to make one award worth $4.0 million in total. Applications closed on June 4, 2024.
From the official notice on Grants.gov, last changed April 18, 2024. Checked November 7, 2026.
- Award ceiling$1.0 million
- Award floor$750,000
- Total funding$4.0 million
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | April 4, 2024 |
|---|---|
| Deadline | June 4, 2024 |
| Archived by Grants.gov | July 4, 2024 |
Who can apply
This opportunity was open to any type of organization.
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Applicants must represent or be an administrative partner to an established state or territorial newborn screening program. Applicants must be able to implement and sustain new newborn screening programs in a U.S. state or territory.
Is this a realistic fit?
- Past Laboratory Leadership, Workforce Training and Management Development, Improving Public Health Laboratory Infrastructure awards averaged $654,875; this notice allows up to $1.0 million per award.
- Most of the program's money (46% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
The use of dried blood spots to screen newborns for serious diseases has had a significant impact in saving lives and improving developmental outcomes since 1963. The adoption of new technologies into public health laboratory workflows has made it possible to screen newborns for an increasing number of diseases. Today, advanced technologies, such as Next Generation Whole Genome Sequencing and High-Resolution Mass Spectrometry, can enhance key aspects of newborn screening (NBS) practice, including early detection of current and newly added diseases. However, incorporating these advanced and complex technologies into NBS often requires substantial resources. To enhance NBS practice, CDC announces a new NOFO for a public health laboratory to establish a NBS Center of Excellence that will 1) develop infrastructure to implement existing, advanced technologies to expand NBS system capacity, 2) use advanced technologies as second and third tier testing platforms to optimize screening performance, and 3) incorporate bio-informatics to analyze complex biochemical and molecular data. Over the four-year project, the recipient will pilot methods to enhance NBS practices in public health laboratories, collaborate and share findings with the NBS community, and partner with CDC subject-matter experts on data harmonization and modernization efforts. This project will better position NBS programs to adapt to advanced technologies and meet increasing demands within NBS.
Who has won Laboratory Leadership, Workforce Training and Management Development, Improving Public Health Laboratory Infrastructure grants before
From fiscal 2021 to 2025, Laboratory Leadership, Workforce Training and Management Development, Improving Public Health Laboratory Infrastructure (93.065) awarded $19.6 million across 30 grant awards, an average of $654,875 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Association of Public Health Laboratories, Inc. (the) | Maryland | 2 | $7.0 million |
| National Center for Farmworker Health, Inc. | Texas | 1 | $4.0 million |
| National Foundation for the Centers for Disease Control & Prevention, Inc. | Georgia | 1 | $1.0 million |
| Department of State Health Services | Texas | 2 | $990,590 |
| University of Wisconsin System | Wisconsin | 1 | $872,084 |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-EH-24-0044 still open?
No. It closed on June 4, 2024.
Who can apply for Centers of Excellence to Enhance Disease Detection in Newborns?
Centers for Disease Control - NCEH accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Centers of Excellence to Enhance Disease Detection in Newborns?
Closed June 4, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $1.0 million each. About $4.0 million in total for one award.
Who has won Laboratory Leadership, Workforce Training and Management Development, Improving Public Health Laboratory Infrastructure grants before?
The largest recipients over five fiscal years were Association of Public Health Laboratories, Inc. (the), National Center for Farmworker Health, Inc., National Foundation for the Centers for Disease Control & Prevention, Inc. The program made 30 awards worth $19.6 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)